EASTERN COOPERATIVE ONCOLOGY GROUP

这项建议的主要目的是确保资金，以帮助 支持范德比尔特大学的临床癌症研究。 从10月开始， 1977年至1986年6月，临床研究得到部分资金支持 通过东南癌症研究小组获得。 与 解散SECSG，范德比尔特调查人员寻求并获得了 东部肿瘤协作组的成员。 西非经共体成员 在融资周期结束时，只有有限的“启动”资金 已经准备好协助这一过渡。 的具体目标 这一建议包括：1）增加全集团阶段参与 II期和III期临床试验，2）开发创新治疗 肺癌、睾丸癌、淋巴瘤和其他 恶性肿瘤，3）参与和开展药理学研究 与正在进行的ECOG试验联合使用，4） 正在进行的全组骨髓移植研究和开发 新的研究，5）并保持高质量的数据管理， 在我们与SECSG的长期合作中建立的。 这些 目标将通过调查人员的密切合作来实现 来自肿瘤内科和血液科， 来自放射肿瘤学、外科和 病理 范德比尔特研究人员是几种疾病的成员- 指导委员会，并主持了几项试点和全集团的研究。 我们 骨髓移植服务是ECOG批准的。 我们有一个 杰出的临床药理学项目，已建立， 积极参加了联合国儿童基金会的活动。 总之，范德比尔特 研究人员准备成为ECOG的主要贡献者， 患者的收益以及创新的发展 治疗方案。

The primary objective of this proposal is to secure funding to help support clinical cancer research at Vanderbilt University. From October, 1977 until June, 1986, clinical research was partly supported by funds obtained through the Southeastern Cancer Study Group. With the disbanding of the SECSG, Vanderbilt investigators sought and obtained membership in the Eastern Cooperative Oncology Group. Membership in ECOG came at the end of a funding cycle and only limited "start-up" funds have been made available to assist in this transition. The specific aims of this proposal include: 1) to increase participation in group-wide phase II and phase III clinical trials, 2) to develop innovative treatment protocols for lung cancer, testicular cancer, lymphomas and other malignancies, 3) participation in and development of pharmacology studies to be used in conjunction with ongoing ECOG trials, 4) collaboration in ongoing group-wide bone marrow transplantation studies and development of new studies, 5) and to maintain the high quality of data management as previously established during our long association with SECSG. These goals will be obtained through the close cooperation of investigators from the divisions of medical oncology and hematology and the assistance of investigators from the departments of radiation oncology, surgery and pathology. Vanderbilt investigators are members of several disease- oriented committees and chair several pilot and group-wide studies. Our bone marrow transplantation service is ECOG approved. We have an outstanding clinical pharmacology program which is well established and is actively participating in ECOG activities. In summary, Vanderbilt investigators are poised to become major contributors to ECOG both in terms of patient accrual as well as the development of innovative treatment protocols.